Navigation Links
Omeros Appoints New Vice President of Clinical Development
Date:8/5/2009

SEATTLE, Aug. 5 /PRNewswire/ -- Omeros Corporation today announced the appointment of Stephen R. Murray, M.D., Ph.D. as Vice President of Clinical Development. Dr. Murray will oversee clinical trial strategies and protocols at Omeros, and currently is leading the ongoing clinical studies for Omeros' PharmacoSurgery(TM) product candidates. These include OMS103HP, the Company's lead candidate being evaluated in a Phase 3 clinical program for improved joint function and pain reduction following arthroscopic surgery, OMS302 in a Phase 2 program for use in cataract surgery, and OMS201 in a Phase 1/2 program for use in uroendoscopy.

"Dr. Murray brings a wealth of experience in the pharmaceutical industry, having successfully directed a number of development programs in both large and small pharmaceutical companies," said Gregory A. Demopulos, M.D., Chairman & CEO of Omeros. "Dr. Murray will work closely with our team members to continue building the long-term value of Omeros and our products."

"Omeros is poised to deliver important new treatments to patients through its PharmacoSurgery platform," said Dr. Murray. "In addition, we have several preclinical central nervous system and inflammation programs that have the potential to address significant unmet medical needs. This is an important time for Omeros and I'm excited to play a role here."

Prior to Omeros, Dr. Murray served in various positions, most recently as Chief Medical Officer at Memory Pharmaceuticals, a biopharmaceutical company that developed treatments for central nervous system disorders and was acquired by Hoffman-La Roche Inc. in January 2009. Before that, Dr. Murray held various positions at Pfizer Global Pharmaceuticals, including senior medical director and therapeutic team leader for schizophrenia. Dr. Murray received his M.D. and Ph.D. in molecular and cellular biology from the Medical University of South Carolina and completed his training in psychiatry at the University of California--San Francisco. He is replacing Paul Strauss, M.D., who will continue to work with the Company on a consulting basis.

About Omeros Corporation

Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. For more information on Omeros, visit the Company's Web site at www.omeros.com.


'/>"/>
SOURCE Omeros Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinsons Disease Target
2. Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery
3. Omeros and BlueCrest Announce $20 Million Debt Facility
4. Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
5. Omeros Appoints David A. Mann to its Board of Directors
6. Omeros Corporation Files Registration Statement for Proposed Initial Public Offering
7. Oncothyreon appoints Diana Hausman as Vice President of Clinical Development
8. Cephalon Appoints Craig C. Phillips as Vice President and General Manager of Oncology Business Unit
9. Brookstone Pharmaceuticals Appoints New Corporate Position
10. PDI Appoints Gerald P. Belle as Lead Independent Director
11. Laureate Pharma Appoints Daniel E. Leone as Vice President of Business Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... 2016 , ... Last week, Callan Capital, an integrated wealth management firm specializing ... of San Diego Life Science event at the Estancia La Jolla Resort and Spa. ... with speakers Dr. Rich Heyman, former CEO of Aragon and Seragon, and Faheem Hasnain, ...
(Date:5/23/2016)... ... 23, 2016 , ... The need for blood donations in South Texas and across the nation ... Blood & Tissue Center, blood donations are on the decline. In fact, donations across the ... 21 percent in South Texas in the last four years alone. , There is no ...
(Date:5/23/2016)... , May 23, 2016 Zimmer Biomet Holdings, ... healthcare, today announced that its Board of Directors has approved ... the second quarter of 2016. The cash ... about July 29, 2016 to stockholders of record as of ... of dividends are subject to approval of the Board of ...
(Date:5/23/2016)... LONDON , May 23, 2016 ... Efficiency by 40% - Frontage Implement a Single Platform ... Quality, Compliance and Traceability Within the Bioanalytical lab Frontage ... the United States and China ... across its laboratory facilities. In addition to serving as the global ...
Breaking Biology Technology:
(Date:3/14/2016)... http://www.apimages.com ) - ... - Renvoi : image disponible via AP Images ( ... --> DERMALOG, le leader de l,innovation ... d,empreintes digitales pour l,enregistrement des réfugiés en Allemagne. ... produire des cartes d,identité aux réfugiés. DERMALOG dévoilera ...
(Date:3/10/2016)... 2016 --> ... "Identity and Access Management Market by Component (Provisioning, Directory ... by Organization Size, by Deployment, by Vertical, and by ... The market is estimated to grow from USD 7.20 ... at a Compound Annual Growth Rate (CAGR) of 12.2% ...
(Date:3/9/2016)... , March 9, 2016 ... government identified that more than 23,000 public service employees ... had been receiving their salary unlawfully.    --> ... country,s government identified that more than 23,000 public service ... or had been receiving their salary unlawfully.    ...
Breaking Biology News(10 mins):